Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) δ agonists
摘要:
A series of 1,4-benzyloxybenzylsulfanylaryl carboxylic acids were prepared and their activities for PPAR receptor subtypes (alpha, beta, and gamma) with potential indications for the treatment of dyslipidemia were investigated. Analog 13a displayed the greatest binding affinity (IC50 = 10 nM) and selectivity (120-fold) for PPAR delta over PPAR alpha. Many of the analogs investigated were found to be highly selective for PPAR delta and were dependent on the point of attachment of the substituent. In the 1,4-series, analog 28e was found to be the most potent (IC50 = 1.7 nM) and selective (> 1000-fold) compound for PPAR delta. None of the compounds tested showed appreciable binding affinity for PPAR gamma. (c) 2007 Elsevier Ltd. All rights reserved.
Compounds that modulate PPAR activity and methods of preparation
申请人:——
公开号:US20030207916A1
公开(公告)日:2003-11-06
This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
THIAZOLE AND OXAZOLE DERIVATIVES THAT MODULATE PPAR ACTIVITY
申请人:Warner-Lambert Company LLC
公开号:EP1485091A1
公开(公告)日:2004-12-15
INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
申请人:Gilead Sciences, Inc.
公开号:EP2220046B1
公开(公告)日:2014-06-18
US6833380B2
申请人:——
公开号:US6833380B2
公开(公告)日:2004-12-21
[EN] THIAZOLE AND OXAZOLE DERIVATIVES THAT MODULATE PPAR ACTIVITY<br/>[FR] DERIVES DE THIAZOLE ET D'OXAZOLE QUI MODULENT L'ACTIVITE DU RECEPTEUR PPAR
申请人:WARNER LAMBERT CO
公开号:WO2003074052A1
公开(公告)日:2003-09-12
This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.